20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
23:09 , Feb 6, 2018 |  BC Extra  |  Financial News

EdRIP unveils new €345 million fund

Edmond de Rothschild Investment Partners closed its fifth fund, BioDiscovery 5, at €345 million ($428 million), one of the largest European VC funds focused on life sciences ever, according to BioCentury’s BCIQ database. The fund...
23:05 , Feb 6, 2018 |  BioCentury  |  Finance

Stepping up in Europe

After closing one of Europe’s largest ever life sciences VC funds, Edmond de Rothschild Investment Partners now has the firepower to follow portfolio companies longer and put more capital to work in a wider variety...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Financial News

GamaMabs Pharma completes venture financing

GamaMabs Pharma S.A. , Toulouse, France   Business: Cancer, Antibodies   Date completed: 2015-12-15   Type: Venture financing   Raised: EUR15 million ($16.4 million)   Investors: BioDiscovery 4; InnoBio Fund; IRDINov; Alto Invest; iXO Private...
08:00 , Dec 15, 2015 |  BC Extra  |  Financial News

GamaMabs raises EUR 15M in series B

GamaMabs Pharma S.A. (Tolouse, France) raised EUR 15 million ($16.4 million) in a series B round led by new investor Edmond de Rothschild Investment Partners (EdRIP) via its BioDiscovery 4 fund. Existing investors InnoBio, Irdinov,...
07:00 , May 26, 2014 |  BioCentury  |  Finance

Europe's Iceberg 2014: Divergent appetites

BioCentury's 12th annual European Iceberg survey projects one of the lowest financing demand figures ever for public biotechs, thanks to the robust funding environment over the last two years. But while private companies actually raised...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Financial News

Edmond de Rothschild Investment Partners financial update

Edmond de Rothschild Investment Partners closed BioDiscovery 4 with €192 million ($265.2 million). Last year, the firm raised €125 million ($153.6 million) in an initial close of its fourth dedicated life sciences fund. EdRIP plans...
02:03 , Nov 5, 2013 |  BC Extra  |  Financial News

EdRIP closes BioDiscovery 4 with EUR 192 million

Edmond de Rothschild Investment Partners closed BioDiscovery 4 with EUR 192 million ($265.2 million). Last year, the firm raised EUR 125 million ($153.6 million) in an initial close of its fourth dedicated life sciences fund....
08:00 , Nov 4, 2013 |  BioCentury  |  Finance

Rothschild racks up

Edmond de Rothschild Investment Partners is sticking with its investment strategy for the firm's fourth dedicated life sciences fund - an approach that has allowed it to return money to LPs every year since 2004...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Demand disequilibrium

BioCentury's 11th annual European Iceberg survey sees funding demand continue to fall for a shrinking number of public clinical-stage biotechs in Europe, while the capital demanded by the growing cadre of venture biotechs continues to...